Mortality Benefit Among Primary Prevention Implantable Cardioverter-Defibrillator Recipients on Contemporary Heart Failure Treatment.

Saved in:
Bibliographic Details
Title: Mortality Benefit Among Primary Prevention Implantable Cardioverter-Defibrillator Recipients on Contemporary Heart Failure Treatment.
Authors: Ahmed A; Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA. Electronic address: aamirahm@buffalo.edu., Auricchio A; Division of Cardiology, Istituto Cardiocentro Ticino - Ente Ospedaliero Cantonale, Lugano, Switzerland., Mittal S; The Valley Health System and the Snyder Center for Comprehensive Atrial Fibrillation, Ridgewood, New Jersey, USA., Pickett RA; Saint Thomas Research Institute, Nashville, Tennessee, USA., Wilkoff BL; Cleveland Clinic Heart, Thoracic, and Vascular Institute, Cleveland, Ohio, USA., Jacobsen LD; Medtronic, Mounds View, Minnesota, USA., Marti AK; Medtronic, Mounds View, Minnesota, USA., Holbrook RW; Medtronic, Mounds View, Minnesota, USA., Soderlund DM; Medtronic, Mounds View, Minnesota, USA., Curtis AB; Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA.
Source: JACC. Clinical electrophysiology [JACC Clin Electrophysiol] 2024 May; Vol. 10 (5), pp. 916-926. Date of Electronic Publication: 2024 Mar 20.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101656995 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2405-5018 (Electronic) Linking ISSN: 2405500X NLM ISO Abbreviation: JACC Clin Electrophysiol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2405-5018
DOI:10.1016/j.jacep.2024.102334